Phase I study of hycanthone.
Hycanthone, an antischistosomal drug possessing activity against experimental murine tumors, was administered by 20-minute infusion daily x 5 days to 12 patients with advanced cancer to determine dose-limiting toxicity and to look for therapeutic effect. No objective responses were seen. The dose-limiting toxic effect was acute hepatitis occurring in two of four patients treated at 100 mg/m2/day x 5. Moderate nausea and vomiting occurring on treatment days was the only other toxic effect. Hycanthone was not myelosuppressive. Assay of plasma concentrations of hycanthone revealed a plasma half-life of 3-5 hours and no accumulation of drug over the 5 days of treatment.
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury; D004341:Drug Evaluation; D006207:Half-Life; D006801:Humans; D006826:Hycanthone / Q000097:blood / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D013892:Thioxanthenes / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D013892:Thioxanthenes; D006826:Hycanthone